Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
None
CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

The purpose of this study is to evaluate long-term safety and tolerability data in eligible CLCZ696B2319 (PANORAMA-HF) patients receiving open-label sacubitril/valsartan.

valsartan
  • 5 views
  • 16 Dec, 2021
  • 65 locations
None
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

The purpose of this study is to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a

ventricular angiography
heart failure
enalapril
nt-probnp
b-type natriuretic peptide
  • 0 views
  • 12 Dec, 2021
  • 44 locations
None
Sacubitril/Valsartan in Resistant Hypertension

The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in patients with resistant hypertension compared to the use of recommended and optimized antihypertensive

  • 0 views
  • 27 Jan, 2021
  • 2 locations
None
Sacubitril/Valsartan in Left Ventricular Assist Device Recipients

The primary objective of this study is to assess the safety and tolerability of sacubitril/valsartan compared with standard of care used for treating BP in patients that have been implanted with

  • 0 views
  • 08 May, 2021
  • 1 location
None
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and …

heart disease
hiv viral load
aldosterone
antiretroviral agents
antiretroviral therapy
  • 0 views
  • 20 Oct, 2021
None
Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

A randomized and parallel controlled trial design of comparing the new treatment group of Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment group of

dialysis
valsartan
erythropoietin
angiotensin ii receptor antagonists
  • 0 views
  • 30 Sep, 2021
  • 1 location
None
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas.

calcitonin
gastrin
cancer
targeted therapy
dotatate
  • 0 views
  • 10 Oct, 2021
  • 1 location
None
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

The study will assess the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on cardiac oxygen consumption and the efficiency of cardiac work in

heart failure
valsartan
  • 4 views
  • 13 Dec, 2021
  • 1 location
None
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

survival rate and quality of life. Sacubitril/Valsartan is recommended as a first-line option for treating symptomatic chronic heart failure, especially HF with reduced ejection fraction (HFrEF

chronic heart failure
nt-probnp
ejection fraction
n-terminal pro-bnp
b-type natriuretic peptide
  • 23 views
  • 26 Jan, 2021
  • 1 location
None
Prevention of Cardiac Dysfunction During Breast Cancer Therapy

heart failure treatment. In smaller studies angiotensin antagonists have shown to have a cardioprotective effect during breast cancer treatment. Sacubitril/valsartan is a potent drug that in addition to

MRI
cancer
enalapril
heart failure
valsartan
  • 1 views
  • 22 Aug, 2021
  • 4 locations